These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

126 related articles for article (PubMed ID: 34825396)

  • 21. Future Therapeutics in Alzheimer's Disease: Development Status of BACE Inhibitors.
    Evin G
    BioDrugs; 2016 Jun; 30(3):173-94. PubMed ID: 27023706
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Intracellular mechanisms of amyloid accumulation and pathogenesis in Alzheimer's disease.
    Glabe C
    J Mol Neurosci; 2001 Oct; 17(2):137-45. PubMed ID: 11816787
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Expression of apolipoprotein E in Alzheimer's disease and its significance].
    He SR; Liu DG; Wang S; Xia YJ
    Zhonghua Bing Li Xue Za Zhi; 2005 Sep; 34(9):556-60. PubMed ID: 16468304
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Focal-type, but not Diffuse-type, Amyloid Beta Plaques are Correlated with Alzheimer's Neuropathology, Cognitive Dysfunction, and Neuroinflammation in the Human Hippocampus.
    Liu F; Sun J; Wang X; Jin S; Sun F; Wang T; Yuan B; Qiu W; Ma C
    Neurosci Bull; 2022 Oct; 38(10):1125-1138. PubMed ID: 36028642
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Soluble amyloid beta peptide concentration as a predictor of synaptic change in Alzheimer's disease.
    Lue LF; Kuo YM; Roher AE; Brachova L; Shen Y; Sue L; Beach T; Kurth JH; Rydel RE; Rogers J
    Am J Pathol; 1999 Sep; 155(3):853-62. PubMed ID: 10487842
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Impact of TREM2 risk variants on brain region-specific immune activation and plaque microenvironment in Alzheimer's disease patient brain samples.
    Prokop S; Miller KR; Labra SR; Pitkin RM; Hoxha K; Narasimhan S; Changolkar L; Rosenbloom A; Lee VM; Trojanowski JQ
    Acta Neuropathol; 2019 Oct; 138(4):613-630. PubMed ID: 31350575
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Pathology of clinical and preclinical Alzheimer's disease.
    Thal DR; von Arnim C; Griffin WS; Yamaguchi H; Mrak RE; Attems J; Upadhaya AR
    Eur Arch Psychiatry Clin Neurosci; 2013 Nov; 263 Suppl 2():S137-45. PubMed ID: 24077890
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Cerebral amyloid-beta protein accumulation with aging in cotton-top tamarins: a model of early Alzheimer's disease?
    Lemere CA; Oh J; Stanish HA; Peng Y; Pepivani I; Fagan AM; Yamaguchi H; Westmoreland SV; Mansfield KG
    Rejuvenation Res; 2008 Apr; 11(2):321-32. PubMed ID: 18341428
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The coarse-grained plaque: a divergent Aβ plaque-type in early-onset Alzheimer's disease.
    Boon BDC; Bulk M; Jonker AJ; Morrema THJ; van den Berg E; Popovic M; Walter J; Kumar S; van der Lee SJ; Holstege H; Zhu X; Van Nostrand WE; Natté R; van der Weerd L; Bouwman FH; van de Berg WDJ; Rozemuller AJM; Hoozemans JJM
    Acta Neuropathol; 2020 Dec; 140(6):811-830. PubMed ID: 32926214
    [TBL] [Abstract][Full Text] [Related]  

  • 30. β-Amyloid peptides and amyloid plaques in Alzheimer's disease.
    Gouras GK; Olsson TT; Hansson O
    Neurotherapeutics; 2015 Jan; 12(1):3-11. PubMed ID: 25371168
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Pharmacokinetics and Pharmacodynamics of the BACE1 Inhibitor Verubecestat (MK-8931) in Healthy Japanese Adults: A Randomized, Placebo-Controlled Study.
    Chris Min K; Dockendorf MF; Palcza J; Tseng J; Ma L; Stone JA; Kleijn HJ; Hodsman P; Masuo K; Tanen M; Troyer MD; van Vugt M; Forman MS
    Clin Pharmacol Ther; 2019 May; 105(5):1234-1243. PubMed ID: 30347431
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The interaction of insoluble Amyloid-β with soluble Amyloid-β dimers decreases Amyloid-β plaque numbers.
    van Gerresheim EF; Herring A; Gremer L; Müller-Schiffmann A; Keyvani K; Korth C
    Neuropathol Appl Neurobiol; 2021 Aug; 47(5):603-610. PubMed ID: 33338256
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Neuronal spreading and plaque induction of intracellular Aβ and its disruption of Aβ homeostasis.
    Roos TT; Garcia MG; Martinsson I; Mabrouk R; Israelsson B; Deierborg T; Kobro-Flatmoen A; Tanila H; Gouras GK
    Acta Neuropathol; 2021 Oct; 142(4):669-687. PubMed ID: 34272583
    [TBL] [Abstract][Full Text] [Related]  

  • 34. New Insights into the Spontaneous Human Alzheimer's Disease-Like Model Octodon degus: Unraveling Amyloid-β Peptide Aggregation and Age-Related Amyloid Pathology.
    Cisternas P; Zolezzi JM; Lindsay C; Rivera DS; Martinez A; Bozinovic F; Inestrosa NC
    J Alzheimers Dis; 2018; 66(3):1145-1163. PubMed ID: 30412496
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Calsyntenin-3 C-terminal fragment accumulates in dystrophic neurites surrounding aβ plaques in tg2576 mouse and Alzheimer disease brains: its neurotoxic role in mediating dystrophic neurite formation.
    Uchida Y; Gomi F; Murayama S; Takahashi H
    Am J Pathol; 2013 May; 182(5):1718-26. PubMed ID: 23499467
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Use of YFP to study amyloid-beta associated neurite alterations in live brain slices.
    Brendza RP; Simmons K; Bales KR; Paul SM; Goldberg MP; Holtzman DM
    Neurobiol Aging; 2003 Dec; 24(8):1071-7. PubMed ID: 14643378
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Human tau increases amyloid β plaque size but not amyloid β-mediated synapse loss in a novel mouse model of Alzheimer's disease.
    Jackson RJ; Rudinskiy N; Herrmann AG; Croft S; Kim JM; Petrova V; Ramos-Rodriguez JJ; Pitstick R; Wegmann S; Garcia-Alloza M; Carlson GA; Hyman BT; Spires-Jones TL
    Eur J Neurosci; 2016 Dec; 44(12):3056-3066. PubMed ID: 27748574
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Quinacrine directly dissociates amyloid plaques in the brain of 5XFAD transgenic mouse model of Alzheimer's disease.
    Park S; Kim HY; Oh HA; Shin J; Park IW; Yoon S; Woo DH; Kim Y
    Sci Rep; 2021 Jun; 11(1):12043. PubMed ID: 34103615
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Reduced Reelin expression accelerates amyloid-beta plaque formation and tau pathology in transgenic Alzheimer's disease mice.
    Kocherhans S; Madhusudan A; Doehner J; Breu KS; Nitsch RM; Fritschy JM; Knuesel I
    J Neurosci; 2010 Jul; 30(27):9228-40. PubMed ID: 20610758
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The antibody aducanumab reduces Aβ plaques in Alzheimer's disease.
    Sevigny J; Chiao P; Bussière T; Weinreb PH; Williams L; Maier M; Dunstan R; Salloway S; Chen T; Ling Y; O'Gorman J; Qian F; Arastu M; Li M; Chollate S; Brennan MS; Quintero-Monzon O; Scannevin RH; Arnold HM; Engber T; Rhodes K; Ferrero J; Hang Y; Mikulskis A; Grimm J; Hock C; Nitsch RM; Sandrock A
    Nature; 2016 Sep; 537(7618):50-6. PubMed ID: 27582220
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.